8% replicating cells in the FoxP3+ subset. In contrast, MAPK inhibitor TNF treatment resulted in replication of only 10.8% of FoxP3− cells replicating (Fig. 3A right

panels). Thus, IL-7 also enabled TNF to preferentially stimulate the proliferation of Tregs (p<0.001, Fig. 3B). We also investigated the effect of IL-7 with or without TNF on the proliferative responses of flow-sorted CD4+FoxP3/gfp+ Tregs to TCR stimulation. As shown in Fig. 3C, although IL-7 by itself only had minimal effect, a combination of TNF and IL-7 synergistically promoted the proliferation of Tregs. Next, we examined the effects of TNF/IL-7 on the expression of FoxP3 and TNFR2 on Tregs. As shown in Fig. 3D, after 3-day treatment with IL-7 alone, the proportion of FoxP3+ Tregs present in CD4+ T cells was only ∼4%, which was lower than that in freshly isolated CD4+ T cells (∼10%) or CD4+ T cells cultured with IL-2 (10 ng/mL, >10%) selleck inhibitor for 3 days. Even the higher molar concentration of IL-7 was not as effective as IL-2 in the maintenance of survival of Tregs. Nevertheless, TNF in conjunction

with IL-7 was able to increase the proportion of FoxP3+ cells (Fig. 3D), in a dose-dependent manner (Fig. 3E). Furthermore, in the presence of IL-7, TNF increased the proportion of TNFR2+ cells in the FoxP3+ subset, but not in FoxP3− cells (Fig. 3F), indicating that IL-7 could also promulgate the Treg-activating effect of TNF. To eliminate a possible effect of IL-2 released by activated FoxP3− Teffs present in the unfractionated CD4+ T cells, neutralizing anti-IL-2 Ab was used. As shown in Fig. 3G and H, in the presence of as high as 10 μg/mL of neutralizing anti-IL-2 Ab, TNF/IL-7 still Janus kinase (JAK) up-regulated TNFR2 expression on Tregs and expanded FoxP3+ cells (p<0.05). Furthermore, treatment with TNF alone for 24 h also resulted in an increase of TNFR2 expression on Tregs, which was not blocked by the neutralizing anti-IL-2 Ab (Fig. 3I and J). Thus, the effect of TNF on the proliferation of Tregs and up-regulation of TNFR2 on Tregs can occur independently

of IL-2. Next, we examined whether 4-1BB and OX40 induced on Tregs by TNF were functional. As shown in Fig. 4A and B, both agonistic anti-4-1BB and anti-OX40 Abs were able to partially overcome the anergic status of Tregs and induced proliferation of Tregs. Furthermore, the combination of TNF and anti-4-1BB Ab or anti-OX40 Ab synergistically stimulated the proliferation of Tregs (p<0.05–0.001. Fig. 4A and B). In contrast, isotype control IgGs did not have any effect (data not shown). CD4-depleted splenocytes were used as APCs in this study and they expressed OX40L and 4-1BBL (data not shown). We therefore examined the effect of blockade of OX40L and 4-1BBL on the proliferation of Tregs. As shown in Fig. 4C, TNF-induced proliferative responses of CD4+FoxP3/gfp+ Tregs to APC stimulation was partially abrogated by blocking antibodies to OX40L and to a greater extent by anti-4-1BBL Ab (p<0.05).